Cervarix denied FDA priority review

Share this article:

GlaxoSmithKline said yesterday that the FDA has denied the drugmaker its request for a priority review of its experimental cancer vaccine Cervarix.

Cervarix now faces a standard 10-month review, instead of the six-month review usually granted under a priority review. 

A priority review is often only granted to new treatments when no drugs are available for a particular illness. However, Cervarix rival, Merck’s Gardasil, is already on the market. 

GSK expects a Cervarix action date by the FDA in January 2008.

Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.